ClinicalTrials.gg
RecruitingNCT06578078SENEKAUpdated Mar 4, 2026

A Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients

A Phase 3 interventional study of Sodium Zirconium Cyclosilicate and Standard of care treatment (RAASi therapy) in Heart Failure and Chronic Kidney Diseases, sponsored by Fundación para la Investigación del Hospital Clínico de Valencia. Recruiting at 6 sites in Spain. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by Fundación para la Investigación del Hospital Clínico de Valencia · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Heart Failure by Fundación para la Investigación del Hospital Clínico de Valencia — 5 open to participants now, 6 under way, 1 of them phase 3. Heart Failure · Fundación para la Investigación del Hospital Clínico de Valencia.

Planned enrollment
5th of 14
94 · median 64
Started
2024
with 4 others
Phase 3
Only one
of the 14
Registered
10th of 14
by date

Among the 14 studies in Heart Failure by Fundación para la Investigación del Hospital Clínico de Valencia, this one is the 5th largest by planned enrollment, is one of 5 that started in 2024, is the only one in phase 3, and was the 10th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

5 of the 14 studies in Heart Failure by Fundación para la Investigación del Hospital Clínico de Valencia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 70 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Heart Failure by Fundación para la Investigación del Hospital Clínico de Valencia, or all of them as a file.
02

Study summary

Heart failure (HF) and Chronic Kidney Disease (CKD) patients are frequently not administered renin-angiotensin aldosterone system inhibitor (RAASi) therapies at recommended doses due to hyperkalaemia, despite proven mortality and morbidity benefits. Sodium zirconium cyclosilicate (SZC) is a nonabsorbed potassium binder proven to lower serum potassium (S-K) and maintain normokalaemia. The purpose is to assess if a treatment regimen containing SZC will allow RAASi therapies to be optimized to target doses in patients with heart failure, chronic kidney disease and elevated serum potassium or at risk of developing elevated serum potassium.

Read the detailed description

This is a randomized clinical trial, multicentre, parallel group, open label, to evaluate the use of sodium zirconium cyclosilicate (SZC) to optimize RAASi therapy in patients with heart failure and chronic kidney disease, through up-titration of ACEi, ARB, ARNI or MRA therapy according to clinical guidelines (1), without inducing clinically significant hyperkalemia. Eligible subjects will have been admitted to hospital because of an HF (NYHA I- III) decompensation, will have required intravenous diuretics and will have had mild hyperkalaemic values that needed stabilization or be at risk of developing hyperkalaemia. Subjects will be randomised in a 1:1 ratio to receive SZC or none (standard of care treatment without potassium binders) for 3 months while optimizing RAASi therapies according to the European Society of Cardiology (ESC) guidelines.

03

Conditions studied

  • Heart Failure
  • Chronic Kidney Diseases
04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of giving signed which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  • Provision of informed consent form prior to any study specific procedures, sampling and analysis.
  • Individuals must be ≥ 70 years of age at the time of signing the informed consent form.
  • Individuals must have a confirmed diagnosis of Heart Failure (HF) according to clinical practice guidelines functional class I-III (with HFrEF or HFpEF).
  • Individuals must have previously been admitted to hospital due to HF decompensation requiring intravenous diuretics.
  • Individuals must have been stabilised for at least 24-48h of their HF decompensation before randomisation.
  • Individuals must have a confirmed diagnosis of Chronic Kidney Disease defined as a renal impairment of less than 60ml/min/1.73 m2.
  • Individuals receiving background standard of care for HF and treated according to international guidelines. Specific treatment should include RAASi and/or MRA treatment and at least should have been stable for ≥ 4 weeks at maximum tolerated doses.
  • Patients on RAASi blocker treatment with less than or equal to 75% of the maximum recommended dose.
  • Hyperkalemic patients (sK+ 5.1-5.9 mmol/L at screening / study enrolment) or Normokalemic patients at risk of developing HK defining as having a history of hyperkalaemia (sK+ >5.0 mEq/L) within the prior 24 months and sK+ ≥4.5 mEq/L ≤ 5.1 mEq/L at inclusion

Exclusion criteria

Exclusion Criteria:

  • Limited (less than 1 year) according to clinician's criteria, such as but not limited to , with life expectancy of less than 2 years based on investigator's clinical judgement.
  • sK >6 mEq/litre or \<4.5mEq/litre or history of hypokalemic episodes (S-K\<3.5 mEq/L) during the last year.
  • Patients on haemodialysis or haemofiltration
  • functional class IV
  • Patients undergoing treatment with potassium binders.
  • Active tumour undergoing chemotherapy or or malignancy requiring treatment.
  • Symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia. Subjects with atrial fibrillation controlled by medication are permitted.
  • (f) > 550 msec.
  • History of QT prolongation associated with other medications that required discontinuation of that medication.
  • Congenital long QT syndrome.
  • Prior history of to a RAAS blocker drug, including but not limited to development of angioedema, icterus, hepatitis, or neutropenia or thrombocytopenia requiring treatment modification. Addison's disease or other causes of hypoaldosteronism.
  • Patients with a known hypersensitivity to SZC or any of the of the product.
  • Individuals treated with potassium binding resins such as sodium polystyrene sulfonate (SPS, e.g. Kayexalate®) or calcium polystyrene sulfonate (CPS; e.g. Resonium®) or the cation exchange polymer, patiromer sorbitex calcium (Veltassa®) within 7 days prior to the first dose of study drug.
  • Treated with potassium supplements within 7 days prior to randomization. 15. Positive antibody virus surface antigen or hepatitis B virus core antibody, at screening.
  • Known to have tested positive for .
  • Known history of drug or alcohol abuse within 3 year of screening.
  • Involvement in the planning and/or conduct of the study (applies to both Investigator staff and/or staff at the study site).
  • Judgment by the investigator that the subject should not participate in the study if the subject is unlikely to comply with study procedures, restrictions and requirements.
  • Previous enrolment in the present study.
  • Participation in another clinical study with an product during the last 3 months.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
94 participants (estimated)

Study arms

  • Experimental
    SZC group

    Sodium zirconium cyclosilicate with standard of care treatment (RAASi therapy)

    Drug: Sodium Zirconium Cyclosilicate

  • Active comparator
    Control group

    Standard of care treatment (RAASi therapy) without Sodium zirconium cyclosilicate

    Drug: Standard of care treatment (RAASi therapy)

Interventions

  • Use of sodium zirconium cyclosilicate to optimize RAASi therapy, through up-titration of ACEi, ARB, ARNI or MRA therapy according to clinical guidelines

    Also known as: Lokelma

  • DrugStandard of care treatment (RAASi therapy)

    Standard of care treatment (RAASi therapy) without use of sodium zirconium cyclosilicate

06

What researchers measure

Primary outcomes

  1. Number of patients increasing at least 25% of the target doses of RAASi since the screening visit (V0) to 3 months after study inclusion (V9)

    To compare the number of patients achieving an increase of at least 25% of RAASi according to guideline-recommended target doses, in the arm treated with Lokelma plus RAASi versus the arm treated with RAASi without K+ binder, at 3 months after study inclusion.

    Time frame: Through study completion, an average of 3 months

Secondary outcomes

  1. Number of patients achieving at least 50% of the target doses of RAASi since the screening visit (V0) to 3 months after study inclusion (V9)

    To assess the number of patients achieving at least 50% of the target dose of RAASi recommended in the guidelines.

    Time frame: Through study completion, an average of 3 months

  2. Number of patients increasing 50% of RAASi doses since the screening visit (V0) to 3 months after study inclusion (V9)

    To assess the number of patients achieving at least 50% of the target dose of RAASi recommended in the guidelines.

    Time frame: Through study completion, an average of 3 months

Other outcomes

  1. Number of patients achieving at least 50% of the target doses of MRA since the screening visit (V0) to 3 months after study inclusion (V9)

    To assess the number of patients that achieve at least 50% of the target dose recommended in guidelines of Mineralocorticoid receptor antagonist (MRA).

    Time frame: Through study completion, an average of 3 months

  2. Number of patients increasing 50% of MRA doses since the screening visit (V0) to 3 months after study inclusion (V9)

    To assess the number of patients that achieve at least 50% of the target dose recommended in guidelines of Mineralocorticoid receptor antagonist (MRA)

    Time frame: Through study completion, an average of 3 months

  3. Number of patients achieving at least 50% of the target doses of MRA and RAASi since the screening visit (V0) to 3 months after study inclusion (V9)

    To analyse the number of patients achieving at least 50% of the recommended target dose of MRA and achieving at least 50% of the guidelines recommended target dose of RAASi

    Time frame: Through study completion, an average of 3 months

  4. Number of patients increasing 50% of MRA and RAASi doses since the screening visit (V0) to 3 months after study inclusion (V9)

    To analyse the number of patients achieving at least 50% of the recommended target dose of MRA and achieving at least 50% of the guidelines recommended target dose of RAASi

    Time frame: Through study completion, an average of 3 months

  5. Number of patients achieving the target doses of RAASi since the screening visit (V0) to 3 months after study inclusion (V9)

    To evaluate the number of patients achieving the target dose recommended in guidelines of RAASi.

    Time frame: Through study completion, an average of 3 months

  6. Proportion of patients in each group requiring a down titration of RAASi and/or MRA over the study period

    To evaluate the number of patients requiring down titration and discontinuation of RAASi and/or MRA during the study

    Time frame: Through study completion, an average of 3 months

  7. Proportion of patients in each group requiring up titration of RAASi and/or MRA following down titration of RAASi and/or MRA

    To evaluate the number of patients requiring down titration and discontinuation of RAASi and/or MRA during the study

    Time frame: Through study completion, an average of 3 months

  8. Proportion of patients in each group requiring discontinuation of RAASi and/or MRA over the study period.

    To evaluate the number of patients requiring down titration and discontinuation of RAASi and/or MRA during the study

    Time frame: Through study completion, an average of 3 months

  9. Number of patients achieving at least 50% of the target doses of RAASi since the screening visit (V0) to 1 month after study inclusion

    To analyse the number of patients achieving 50% of target doses recommended in guidelines of RAASi at 1 month after study inclusion

    Time frame: Through study completion, an average of 3 months

  10. Number of patients increasing 50% of RAASi doses since the screening visit (V0) to 1 month after study inclusion

    To analyse the number of patients achieving 50% of target doses recommended in guidelines of RAASi at 1 month after study inclusion

    Time frame: Through study completion, an average of 3 months

  11. Number of patients achieving a decrease of at least 5% in NT-proBNP levels since the baseline visit (V1) to 3 months after study inclusion (V9).

    To determine surrogate short-term (90 days) efficacy objective of changes in biomarker levels (NT-proBNP and CA125) evaluated as a decrease of at least 5% from baseline to 3 months after study inclusion.

    Time frame: Through study completion, an average of 3 months

  12. Mean Change in NT-proBNP levels since the baseline visit (V1) to 3 months after study inclusion (V9).

    To determine surrogate short-term (90 days) efficacy objective of changes in biomarker levels (NT-proBNP and CA125) evaluated as a decrease of at least 5% from baseline to 3 months after study inclusion.

    Time frame: Through study completion, an average of 3 months

  13. Number of patients achieving a decrease of at least 5% in CA125 levels since the baseline visit (V1) to 3 months after study inclusion (V9).

    To determine surrogate short-term (90 days) efficacy objective of changes in biomarker levels (NT-proBNP and CA125) evaluated as a decrease of at least 5% from baseline to 3 months after study inclusion.

    Time frame: Through study completion, an average of 3 months

  14. Mean Change in CA125 levels since the baseline visit (V1) to 3 months after study inclusion (V9).

    To determine surrogate short-term (90 days) efficacy objective of changes in biomarker levels (NT-proBNP and CA125) evaluated as a decrease of at least 5% from baseline to 3 months after study inclusion.

    Time frame: Through study completion, an average of 3 months

  15. Mean change on Systolic arterial blood pressure measurement from baseline visit (V1) to 3 months after study inclusion (V9).

    To explore changes in systolic arterial blood pressure at baseline and 3 months after study inclusion.

    Time frame: Through study completion, an average of 3 months

  16. Mean change from baseline visit (V1) measured at 3 months after study inclusion (V9) in the overall summary score of KKCQ, as a specific HF patient reported outcome questionnaire.

    To explore the effect of treatment with SZC versus none on Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score.

    Time frame: Through study completion, an average of 3 months

  17. To determine the change in renal function the Mean Change in UACR and Mean change in HCO3 will be calculated between baseline visit (V1) and 3 months after study inclusion (V9)

    To evaluate changes in renal function at baseline and 3 months after study inclusion between both groups

    Time frame: Through study completion, an average of 3 months

  18. Number of patients decreasing at least 40% the eGFR since the screening visit (V0) to 3 months after study inclusion (V9).

    To analyse the number of patients that decrease at least 40% in estimated glomerular filtration rate (eGFR) by the CDK-EPI formula.

    Time frame: Through study completion, an average of 3 months

  19. Mean change from baseline visit (V1) measured at 3 months after study inclusion (V9) in the overall summary score of KDQoL, as a specific CKD patient reported outcome questionnaire.

    To explore the effect of treatment with SZC versus none on the Kidney Disease Questionnaire of life (KDQoL) Overall Summary Score.

    Time frame: Through study completion, an average of 3 months

  20. Number of visits for HF/HK/impaired renal function/hypertension or hyperkalemia diagnosed in the outpatient clinic.

    To determine the number of visits to the emergency department for HF/HK/impaired renal function/hypertension (defined as BP over 200 and/or 100 mmHg) and hyperkalemia diagnosed in the outpatient clinic.

    Time frame: Through study completion, an average of 3 months

  21. Proportion of patients requiring hospitalization for HF/HK/impaired renal function over the study period.

    To analyse the number of admissions for HF/HK/impaired renal function.

    Time frame: Through study completion, an average of 3 months

  22. Mean number of hospitalizations per patient for HF/HK/impaired renal function over the study period.

    To analyse the number of admissions for HF/HK/impaired renal function.

    Time frame: Through study completion, an average of 3 months

  23. Proportion of patients presenting at least one clinical event over the study period

    To evaluate in both experimental groups the combined endpoint of visits to the emergency department or admission for HF/HK/impaired renal function or decrease of at least 40% in estimated glomerular filtration rate (eGFR) by the CDK-EPI formula or death from cardiovascular causes.

    Time frame: Through study completion, an average of 3 months

  24. Proportion of patients presenting more than one clinical event over the study period

    To evaluate in both experimental groups the combined endpoint of visits to the emergency department or admission for HF/HK/impaired renal function or decrease of at least 40% in estimated glomerular filtration rate (eGFR) by the CDK-EPI formula or death from cardiovascular causes.

    Time frame: Through study completion, an average of 3 months

  25. Proportion of patients presenting all clinical events over the study period

    To evaluate in both experimental groups the combined endpoint of visits to the emergency department or admission for HF/HK/impaired renal function or decrease of at least 40% in estimated glomerular filtration rate (eGFR) by the CDK-EPI formula or death from cardiovascular causes.

    Time frame: Through study completion, an average of 3 months

  26. Percentage of patients treated with and without sodium-glucose cotransporter-2 (SGLT2) inhibitors over the study period in both arms

    To analyse the percentage of patients with HF treated with and without sodium-glucose cotransporter-2 (SGLT2) inhibitors.

    Time frame: Through study completion, an average of 3 months

  27. Mean Change in Mg levels since the baseline visit (V1) to 3 months after study inclusion (V9).

    To explore changes in Mg levels at baseline and 3 months after study inclusion.

    Time frame: Through study completion, an average of 3 months

  28. Proportion of patients presenting each clinical outcome over the study period: Adverse events, Serious adverse events, Changes in clinical laboratory parameters, Changes in vital signs and ECGs

    To evaluate the safety and tolerability of SZC in this patient population.

    Time frame: Through study completion, an average of 3 months

07

Study locations

3 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.

Of 87 non-industry phase 3 interventional studies under Heart Failure, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 26 months is below that.

Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2024
First posted
Aug 29, 2024
StartActual
Oct 3, 2024
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06578078
Lead sponsor
Fundación para la Investigación del Hospital Clínico de Valencia
Responsible party
Sponsor
First posted
Aug 29, 2024
Start date
Oct 3, 2024
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Mar 4, 2026

Study contacts

Clara Bonanad Lozano
Contact
clarabonanad@gmail.com
+34 963156181

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium zirconium cyclosilicate

Start the discussion